Current experience with clindamycin in the treatment of abdominal and female pelvic infections.
Clindamycin had been used in treatment of severe abdominal and female pelvic infections for over fifteen years. On the basis of several prospective trials, clindamycin has equivalent efficacy to other anti-anaerobe drugs such as cefoxitin and metronidazole. Clindamycin had proven to be superior to cephalothin, cefamandole and cefoperazone in intraabdominal infections. It also produces better results than various penicillins in a variety of obstetrical and gynecological infections. In one study, tubo-ovarian abscess healed significantly better on medical therapy when clindamycin was included in the regimen. Considering the long tract record of favorable results, clindamycin can be considered the "gold standard" by which other anti-anaerobe therapies of abdominal and female pelvic infections are judged.
D000005:Abdomen; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy*; D001442:Bacteroides Infections / Q000188:drug therapy; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D011446:Prospective Studies; D051381:Rats; D011919:Rats, Inbred Strains
D008795:Metronidazole; D002981:Clindamycin